Clinical Overview

The 2021 CKD-EPI creatinine equation is a bedside decision-support calculation used to standardize a defined part of clinical assessment. It estimates normalized GFR in adults without a race coefficient from standardized creatinine, age, and sex. The result should be interpreted with the patient’s presentation, baseline function, serial observations, laboratory method, medication exposure, and the protocol used by the treating institution. It is an aid to communication and risk stratification rather than an independent diagnosis or treatment order.

Enter contemporaneous values and confirm every unit before calculating. When physiology is changing, repeat assessment and prioritize the clinical trajectory over a single number. Document the input values alongside the result so another clinician can reproduce the calculation and recognize assumptions. Thresholds describe populations and do not remove the need to investigate discordant symptoms, examination findings, imaging, or biomarkers.

When to Use

• Adults aged 18 years or older with stable serum creatinine
• CKD detection, staging context, and longitudinal monitoring

Limitations & Safety

It assumes steady-state creatinine and is not a direct measure; drug dosing may require non-indexed GFR or a different validated method. Validation cohorts, case mix, prevalence, and treatment era affect observed event rates. Pregnancy, extremes of age or body composition, critical illness, and major comorbidity may reduce transportability unless specifically represented in the original model. Do not extrapolate beyond the stated population or substitute this estimate for a validated local pathway.

Before acting, check for missing data, measurement error, competing diagnoses, contraindications, and time-sensitive emergencies. A low-risk label never overrides clinician concern; a high-risk label does not prove the target condition. Discuss consequential decisions with the appropriate senior or specialty team and use current regional guidance.

• Not reliable during rapidly changing creatinine or acute kidney injury
• Creatinine may misrepresent filtration at extremes of muscle mass, diet, or amputation

Formula / Scoring Criteria

eGFR = 142 × min(Scr/κ,1)^α × max(Scr/κ,1)^−1.200 × 0.9938^Age × 1.012 if female; κ=0.7 female/0.9 male; α=−0.241 female/−0.302 male

Interpretation

• ≥90 — G1: Normal or high GFR. CKD only if another marker of kidney damage persists.
• 60–89 — G2: Mildly decreased. Interpret with albuminuria and other kidney-damage markers.
• 45–59 / 30–44 — G3a / G3b: Mild–moderate / moderate–severe reduction. Risk-stratify using albuminuria, complications, and trajectory.
• 15–29 / <15 — G4 / G5: Severe reduction / kidney failure category. Urgent specialist planning according to symptoms and trajectory.

Evidence & References

1. KDIGO 2024 Clinical Practice Guideline for CKD.
2. Inker LA, et al. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. NEJM. 2021.

Clinical FAQs

Can one low eGFR diagnose CKD?

No. CKD generally requires abnormality lasting at least three months or other persistent evidence of kidney damage.

Why convert µmol/L?

The equation uses mg/dL; divide creatinine in µmol/L by 88.4 before applying it.

Is eGFR reliable in acute kidney injury?

No. Rapidly changing creatinine violates the steady-state assumption.